Artikel ; Online: HSD17B13 and other liver fat-modulating genes predict development of hepatocellular carcinoma among HCV-positive cirrhotics with and without viral clearance after DAA treatment.
Clinical journal of gastroenterology
2022 Band 15, Heft 2, Seite(n) 301–309
Abstract: Background: Genetic predisposition to accumulate liver fat (expressed by a polygenic risk score, GRS, based on the number of at-risk alleles of PNPLA3, TM6SF2, MBOAT7 and GCKR) may influence the probability of developing hepatocellular carcinoma (HCC) ... ...
Abstract | Background: Genetic predisposition to accumulate liver fat (expressed by a polygenic risk score, GRS, based on the number of at-risk alleles of PNPLA3, TM6SF2, MBOAT7 and GCKR) may influence the probability of developing hepatocellular carcinoma (HCC) after hepatitis C treatment. Whether this holds true taking into account carriage of the HSD17B13:TA splice variant, also affecting lipogenesis, and achievement of viral clearance (SVR), is unknown. Methods: PNPLA3, TM6SF2, MBOAT7, GCKR and HSD17B13 variants were determined in a cohort of 328 cirrhotic patients free of HCC before starting treatment with direct acting antivirals (DAA). Results: SVR in the study cohort was 96%. At the end of follow-up, N = 21 patients had been diagnosed an HCC; none of the genes included in the GRS was individually associated with HCC development. However, in a Cox proportional hazards model, a GRS > 0.457 predicted HCC independently of sex, diabetes, albumin, INR and FIB4. The fit of the model improved adding treatment outcome and carriage of the HSD17B13:TA splice variant, with sex, GRS > 0.457, HSD17B13:TA splice variant and failure to achieve an SVR (hazard ratio = 6.75, 4.24, 0.24 and 7.7, respectively) being independent predictors of HCC. Conclusion: Our findings confirm that genes modulating liver fat and lipogenesis are important risk factors for HCC development among cirrhotics C treated with DAA. |
---|---|
Mesh-Begriff(e) | 17-Hydroxysteroid Dehydrogenases/genetics ; Antiviral Agents/therapeutic use ; Carcinoma, Hepatocellular/genetics ; Carcinoma, Hepatocellular/pathology ; Hepatitis C, Chronic/complications ; Hepatitis C, Chronic/drug therapy ; Humans ; Liver Cirrhosis/complications ; Liver Cirrhosis/drug therapy ; Liver Neoplasms/complications ; Liver Neoplasms/genetics |
Chemische Substanzen | Antiviral Agents ; 17-Hydroxysteroid Dehydrogenases (EC 1.1.-) ; HSD17B13 protein, human (EC 1.1.-.-) |
Sprache | Englisch |
Erscheinungsdatum | 2022-01-31 |
Erscheinungsland | Japan |
Dokumenttyp | Journal Article |
ZDB-ID | 2429411-1 |
ISSN | 1865-7265 ; 1865-7257 |
ISSN (online) | 1865-7265 |
ISSN | 1865-7257 |
DOI | 10.1007/s12328-021-01578-1 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Volltext online
Zusatzmaterialien
Kategorien
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.